Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Humacyte Inc (HUMA)

Humacyte Inc (HUMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Humacyte (HUMA) Faces Regulatory Scrutiny as FDA Raises Quality Concerns

Humacyte (HUMA) experienced a decline of 1.94% in its latest trading session, closing at $5.05, which was slightly more than the S&P 500's 1.86% daily loss. Over the past month, Humacyte's shares have...

HUMA : 5.26 (-2.41%)
Insider Sale: Director at Humacyte (HUMA) Sells 1,548 Shares

Kathleen Sebelius, a director at Humacyte ($HUMA), sold 1,548 shares of the company on 09-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.6% of their...

HUMA : 5.26 (-2.41%)
Humacyte (HUMA) Faces Shareholder Scrutiny After FDA Compliance Issues

Humacyte (HUMA), a biotechnology firm specializing in acellular tissue-engineered vessels, recently encountered significant challenges due to regulatory issues with the U.S. FDA. Following reports of FDA...

HUMA : 5.26 (-2.41%)
Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

HUMA : 5.26 (-2.41%)
Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEVâ„¢) for AV Access in Hemodialysis on October 31, 2024

HUMA : 5.26 (-2.41%)
Humacyte’s $30 Million Stock Offering Fuels Growth Despite Insider Concerns

Benchmark analyst Bruce Jackson maintained a Buy rating on Humacyte (HUMA) with a price target of $15.00, suggesting a significant upside for the company’s stock. Humacyte shares closed at $5.39 yesterday,...

HUMA : 5.26 (-2.41%)
EXAS : 72.19 (+3.42%)
NEO : 14.01 (+0.07%)
Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

HUMA : 5.26 (-2.41%)
Humacyte Announces Pricing of $30.0 Million Registered Direct Offering

HUMA : 5.26 (-2.41%)
This Surging Small-Cap Biotech Has One Very High-Profile Investor

Humacyte is a pre-revenue biotech company that has delivered outsized gains to shareholders in 2024. But is the small-cap stock a good buy right now?

HUMA : 5.26 (-2.41%)
Last month, we reported on a suspicious stock trade by a U.S. Senator. The stock has now risen 220% since then.

On April 16th, we reported on a stock trade by Senator Tommy Tuberville that looked suspicious to us. The stock has now risen 220% in the month since then. The stock in question was Humacyte, $HUMA. It's...

HUMA : 5.26 (-2.41%)

Barchart Exclusives

Which Way Are Crude Oil Prices Going for the Remainder of 2024?
Crude oil prices have ground lower in a highly volatile way since peaking in April 2024. Contributing to this volatility are the upcoming election, the Israel/Iran conflict, and Opec + flip-flopping from increasing production to not. The recent rally of the US dollar has not helped oil prices find much new buying. During these volatile times, using seasonality can offer a road map of what a market has typically done historically. Will crude prices' dominant seasonal sell pattern work again this season? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar